AveXis and REGENXBIO Sign Licensing Agreement to Develop Therapies for ALS and Rett syndrome – ALS News Today
|
AveXis and REGENXBIO Sign Licensing Agreement to Develop Therapies for ALS and Rett syndrome
ALS News Today AveXis will use REGENXBIO's gene-delivery platform, NAV AAV9 vector, to help it develop therapies for rare, inherited and life-threatening neurological diseases. NAV AAV9 vector delivers a healthy gene, placed inside the shell of an adeno-associated … |
